References
Key articles
McMeekin DS, Filiaci VL, Thigpen JT, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 Jul;106(1):16-22. Abstract
Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005 Aug 6-12;366(9484):491-505. Abstract
Obermair A, Janda M, Baker J, et al. Improved surgical safety after laparoscopic compared to open surgery for apparent early stage endometrial cancer: results from a randomised controlled trial. Eur J Cancer.2012 May;48(8):1147-53.Full text Abstract
Nout RA, Putter H, Jürgenliemk-Schulz IM, et al. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer. 2012 Jul;48(11):1638-48.Full text Abstract
de Boer SM, Powell ME, Mileshkin L, et al; PORTEC Study Group. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Feb 12;19(3):295-309.Full text Abstract
Reference articles
1. World Health Organization. Tumours of the uterine corpus. In: WHO Classification of Tumours Editorial Board, eds. Female genital tumours. WHO classification of tumours, 5th edition, volume 4. Lyon, France: IARC; 2020.Full text
2. Clement PB, Young RH. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol. 2004 May;11(3):117-42. Abstract
3. Fadare O, Liang SX, Ulukus EC, et al. Precursors of endometrial clear cell carcinoma. Am J Surg Pathol. 2006 Dec;30(12):1519-30. Abstract
4. Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005 Sep 15;11(18):6422-30.Full text Abstract
5. Hoffman K, Nekhlyudov L, Deligdisch L. Endometrial carcinoma in elderly women. Gynecol Oncol. 1995 Aug;58(2):198-201. Abstract
6. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009 May;105(2):103-4. [Erratum in: Int J Gynaecol Obstet. 2010 Feb;108(2):176.] Abstract
7. Koskas M, Amant F, Mirza MR, et al. Cancer of the corpus uteri: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(suppl 1):45-60.Full text Abstract
8. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983 Feb;15(1):10-7. Abstract
9. Ryan AJ, Susil B, Jobling TW, et al. Endometrial cancer. Cell Tissue Res. 2005 Oct;322(1):53-61. Abstract
10. Santin AD. HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? Gynecol Oncol. 2003 Mar;88(3):263-5. Abstract
11. Kong D, Suzuki A, Zou TT, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet. 1997 Oct;17(2):143-4. Abstract
12. Risinger JI, Hayes AK, Berchuck A, et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997 Nov 1;57(21):4736-8.Full text Abstract
13. Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000 Feb 15;88(4):814-24. Abstract
14. Reinartz JJ, George E, Lindgren BR, et al. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol. 1994 Oct;25(10):1075-83. Abstract
15. Rolitsky CD, Theil KS, McGaughy VR, et al. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol. 1999 Apr;18(2):138-43. Abstract
16. Santin AD, Bellone S, Van Stedum S, et al. Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol. 2005 Jul;98(1):24-30. Abstract
17. Slomovitz BM, Broaddus RR, Burke TW, et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004 Aug 1;22(15):3126-32.Full text Abstract
18. Hetzel DJ, Wilson TO, Keeney GL, et al. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol. 1992 Nov;47(2):179-85. Abstract
19. Kandoth C, Schultz N, et al; Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 2;497(7447):67-73. [Erratum in: Nature. 2013 Aug 8;500(7461):242.]Full text Abstract
20. Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017 Mar 1;123(5):802-13.Full text Abstract
21. Clarke MA, Long BJ, Del Mar Morillo A, et al. Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis. JAMA Intern Med. 2018 Sep 1;178(9):1210-22.Full text Abstract
22. Lachance JA, Everett EN, Greer B, et al. The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol. 2006 Jun;101(3):470-5. Abstract
23. Soliman PT, Oh JC, Schmeler KM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005 Mar;105(3):575-80. Abstract
24. Gu M, Shi W, Barakat RR, et al. Pap smears in women with endometrial carcinoma. Acta Cytol. 2001 Jul-Aug;45(4):555-60. Abstract
25. Eddy GL, Wojtowycz MA, Piraino PS, et al. Papanicolaou smears by the Bethesda system in endometrial malignancy: utility and prognostic importance. Obstet Gynecol. 1997 Dec;90(6):999-1003. Abstract
26. Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol. 2016 Nov 7;34(35):4225-30.Full text Abstract
27. Kocarnik JM, Compton K, Dean FE, et al; Global Burden of Disease 2019 Cancer Collaboration. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022 Mar 1;8(3):420-44.Full text Abstract
28. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209-49.Full text Abstract
29. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7-33.Full text Abstract
30. National Cancer Institute. Surveillance epidemiology and end results (SEER). Cancer stat facts: uterine cancer. 2022 [internet publication].Full text
31. Clarke MA, Devesa SS, Hammer A, et al. Racial and ethnic differences in hysterectomy-corrected uterine corpus cancer mortality by stage and histologic subtype. JAMA Oncol. 2022 Jun 1;8(6):895-903. Abstract
32. World Health Organization: Global Cancer Observatory. Cancer today. 2020 [internet publication].Full text
33. Horn LC, Meinel A, Handzel R, et al. Histopathology of endometrial hyperplasia and endometrial carcinoma: an update. Ann Diagn Pathol. 2007 Aug;11(4):297-311. Abstract
34. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer. 1985 Jul 15;56(2):403-12.Full text Abstract
35. Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008 May;21(5):591-8.Full text Abstract
36. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995 Feb;85(2):304-13. Abstract
37. Marjoribanks J, Farquhar C, Roberts H, et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017 Jan 17;(1):CD004143.Full text Abstract
38. Koornstra JJ, Mourits MJ, Sijmons RH, et al. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol. 2009 Apr;10(4):400-8. Abstract
39. Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet. 2009 Feb;75(2):141-9. Abstract
40. Lynch HT, Krush AJ, Lemon HM, et al. Tumor variation in families with breast cancer. JAMA. 1972 Dec 25;222(13):1631-5. Abstract
41. Win AK, Reece JC, Ryan S. Family history and risk of endometrial cancer: a systematic review and meta-analysis. Obstet Gynecol. 2015 Jan;125(1):89-98. Abstract
42. Hemminki K, Granstrom C. Familial clustering of ovarian and endometrial cancers. Eur J Cancer. 2004 Jan;40(1):90-5. Abstract
43. Lu KH, Schorge JO, Rodabaugh KJ, et al. Prospective determination of prevalence of Lynch II syndrome in young women with endometrial cancer. J Clin Oncol. 2007 Nov 20;25(33):5158-64. Abstract
44. Thompson D, Easton DF; Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002 Sep 18;94(18):1358-65.Full text Abstract
45. Chubak J, Tworoger SS, Yasui Y, et al. Associations between reproductive and menstrual factors and postmenopausal sex hormone concentrations. Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1296-301. Abstract
46. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000 Jun 7;92(11):924-30.Full text Abstract
47. Dinulescu DM, Ince TA, Quade BJ, et al. Role of K-ras and PTEN in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med. 2005 Jan;11(1):63-70. Abstract
48. Leskela S, Pérez-Mies B, Rosa-Rosa JM, et al. Molecular basis of tumor heterogeneity in endometrial carcinosarcoma. Cancers (Basel). 2019 Jul 9;11(7):964.Full text Abstract
49. Deshpande M, Romanski PA, Rosenwaks Z, et al. Gynecological cancers caused by deficient mismatch repair and microsatellite instability. Cancers (Basel). 2020 Nov 10;12(11):3319.Full text Abstract
50. Kim SR, Pina A, Albert A, et al. Mismatch repair deficiency and prognostic significance in patients with low-risk endometrioid endometrial cancers. Int J Gynecol Cancer. 2020 Jun;30(6):783-8. Abstract
51. Ferriss JS, Erickson BK, Shih IM, et al. Uterine serous carcinoma: key advances and novel treatment approaches. Int J Gynecol Cancer. 2021 Aug;31(8):1165-74.Full text Abstract
52. O'Mara TA, Glubb DM, Amant F, et al. Identification of nine new susceptibility loci for endometrial cancer. Nat Commun. 2018 Aug 9;9(1):3166.Full text Abstract
53. Crosbie EJ, Roberts C, Qian W, et al. Body mass index does not influence post-treatment survival in early stage endometrial cancer: results from the MRC ASTEC trial. Eur J Cancer. 2011 Nov 17;48(6):853-64.Full text Abstract
54. Modesitt SC, Tian C, Kryscio R, et al. Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 Apr;105(1):59-65. Abstract
55. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007 Dec 1;335(7630):1134.Full text Abstract
56. Jenabi E, Poorolajal J. The effect of body mass index on endometrial cancer: a meta-analysis. Public Health. 2015 Jul;129(7):872-80. Abstract
57. Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst. 1996 Aug 21;88(16):1127-35.Full text Abstract
58. Duska L, Shahrokni A, Powell M. Treatment of older women with endometrial cancer: improving outcomes with personalized care. Am Soc Clin Oncol Educ Book. 2016 May 19;35:164-74.Full text Abstract
59. Royal College of Obstetricians and Gynaecologists. Management of endometrial hyperplasia (green-top guideline no. 67). Feb 2016 [internet publication].Full text
60. Travaglino A, Raffone A, Saccone G, et al. Loss of B-cell lymphoma 2 immunohistochemical expression in endometrial hyperplasia: a specific marker of precancer and novel indication for treatment. A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2018 Dec;97(12):1415-26.Full text Abstract
61. Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006 Feb 15;106(4):812-9.Full text Abstract
62. Travaglino A, Raffone A, Saccone G, et al. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019 Apr;74(5):676-87. Abstract
63. Raglan O, Kalliala I, Markozannes G, et al. Risk factors for endometrial cancer: an umbrella review of the literature. Int J Cancer. 2019 Oct 1;145(7):1719-30.Full text Abstract
64. Wu Y, Sun W, Liu H, et al. Age at menopause and risk of developing endometrial cancer: a meta-analysis. Biomed Res Int. 2019 May 29;2019:8584130.Full text Abstract
65. Michels KA, Pfeiffer RM, Brinton LA, et al. Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers. JAMA Oncol. 2018 Apr 1;4(4):516-21.Full text Abstract
66. Karlsson T, Johansson T, Höglund J, et al. Time-dependent effects of oral contraceptive use on breast, ovarian, and endometrial cancers. Cancer Res. 2021 Feb 15;81(4):1153-62.Full text Abstract
67. Neven P, De Muylder X, Van Belle Y, et al. Longitudinal hysteroscopic follow-up during tamoxifen treatment. Lancet. 1998 Jan 3;351(9095):36. Abstract
68. Magriples U, Naftolin F, Schwartz PE, et al. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol. 1993 Mar;11(3):485-90. Abstract
69. Ferguson SE, Soslow RA, Amsterdam A, et al. Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecol Oncol. 2006 May;101(2):322-6. Abstract
70. American College of Obstetricians and Gynecologists. ACOG committee opinion no. 601: tamoxifen and uterine cancer. Jun 2014 [internet publication].Full text
71. Zhang ZH, Su PY, Hao JH, et al. The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies. Int J Gynecol Cancer. 2013 Feb;23(2):294-303. Abstract
72. Luo J, Beresford S, Chen C, et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br J Cancer. 2014 Jul 22;111(7):1432-9.Full text Abstract
73. Saed L, Varse F, Baradaran HR, et al. The effect of diabetes on the risk of endometrial cancer: an updated systematic review and meta-analysis. BMC Cancer. 2019 May 31;19(1):527.Full text Abstract
74. Johnatty SE, Tan YY, Buchanan DD, et al. Family history of cancer predicts endometrial cancer risk independently of Lynch syndrome: implications for genetic counselling. Gynecol Oncol. 2017 Nov;147(2):381-7. Abstract
75. Bubien V, Bonnet F, Brouste V, et al; French Cowden Disease Network. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet. 2013 Jan 18;50(4):255-63. Abstract
76. Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod. 2012 May;27(5):1327-31.Full text Abstract
77. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014 Sep-Oct;20(5):748-58.Full text Abstract
78. Pothuri B, Ramondetta L, Eifel P, et al. Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers. Gynecol Oncol. 2006 Dec;103(3):948-51. Abstract
79. Booth FW, Roberts CK, Laye MJ. Lack of exercise is a major cause of chronic diseases. Compr Physiol. 2012 Apr;2(2):1143-211.Full text Abstract
80. Hidayat K, Zhou HJ, Shi BM. Influence of physical activity at a young age and lifetime physical activity on the risks of 3 obesity-related cancers: systematic review and meta-analysis of observational studies. Nutr Rev. 2020 Jan 1;78(1):1-18.Full text Abstract
81. Alizadeh S, Djafarian K, Alizadeh M, et al. The relation of healthy and Western dietary patterns to the risk of endometrial and ovarian cancers: a systematic review and meta-analysis. Int J Vitam Nutr Res. 2020 Jun;90(3-4):365-75. Abstract
82. Liu ZY, Gao XP, Zhu S, et al. Dietary inflammatory index and risk of gynecological cancers: a systematic review and meta-analysis of observational studies. J Gynecol Oncol. 2019 May;30(3):e23.Full text Abstract
83. Li H, Mao H, Yu Y, et al. Association between dietary fiber and endometrial cancer: a meta-analysis. Nutr Cancer. 2020;72(6):959-67. Abstract
84. Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007 Nov;107(2):159-62. Abstract
85. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006 Jan 19;354(3):261-9.Full text Abstract
86. Renaud MC, Le T. Clinical practice guideline no. 291 - epidemiology and investigations for suspected endometrial cancer. J Obstet Gynaecol Can. 2018 Sep;40(9):e703-11. Abstract
87. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. Dec 2021 [internet publication].Full text
88. Saso S, Chatterjee J, Georgiou E, et al. Endometrial cancer. BMJ. 2011 Jul 6;343:d3954. Abstract
89. Braun MM, Overbeek-Wager EA, Grumbo RJ. Diagnosis and management of endometrial cancer. Am Fam Physician. 2016 Mar 15;93(6):468-74.Full text Abstract
90. Pennant ME, Mehta R, Moody P, et al. Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG. 2017 Feb;124(3):404-11.Full text Abstract
91. Castellano T, Ding K, Moore KN, et al. Simple hysterectomy for cervical cancer: risk factors for failed screening and deviation from screening guidelines. J Low Genit Tract Dis. 2019 Apr;23(2):124-8. Abstract
92. Gredmark T, Kvint S, Havel G, et al. Histopathological findings in women with postmenopausal bleeding. Br J Obstet Gynaecol. 1995 Feb;102(2):133-6. Abstract
93. American College of Radiology. ACR appropriateness criteria: abnormal uterine bleeding. 2020 [internet publication].Full text
94. American College of Obstetricians and Gynecologists. ACOG committee opinion no. 734: the role of transvaginal ultrasonography in evaluating the endometrium of women with postmenopausal bleeding. Obstet Gynecol. 2018 May;131(5):e124-9.Full text Abstract
95. American Institute of Ultrasound in Medicine, American College of Radiology, American College of Obstetricians and Gynecologists, Society of Radiologists in Ultrasound. AIUM practice guideline for the performance of sonohysterography. J Ultrasound Med. 2015 Aug;34(8):1-6. Abstract
96. Larson DM, Johnson KK, Broste SK, et al. Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer. Obstet Gynecol. 1995 Jul;86(1):38-42. Abstract
97. Huang GS, Gebb JS, Einstein, MH, et al. Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. Am J Obstet Gynecol. 2007 Mar;196(3):243.e1-5. Abstract
98. Schnatz PF, Guile M, O'Sullivan DM, et al. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol. 2006 Mar;107(3):701-8. Abstract
99. Oaknin A, Bosse TJ, Creutzberg CL, et al. Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Sep;33(9):860-77.Full text Abstract
100. American College of Radiology. ACR appropriateness criteria: pretreatment evaluation and follow-up of endometrial cancer. 2020 [internet publication].Full text
101. Chang MC, Chen JH, Liang JA, et al. 18F-FDG PET or PET/CT for detection of metastatic lymph nodes in patients with endometrial cancer: a systematic review and meta-analysis. Eur J Radiol. 2012 Nov;81(11):3511-7. Abstract
102. Kitajima K, Murakami K, Yamasaki E, et al. Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer. Ann Nucl Med. 2008 Mar 3;22(2):103-9. Abstract
103. Sharma P, Kumar R, Singh H, et al. Carcinoma endometrium: role of 18-FDG PET/CT for detection of suspected recurrence. Clin Nucl Med. 2012 Jul;37(7):649-55. Abstract
104. Kadkhodayan S, Shahriari S, Treglia G, et al. Accuracy of 18-F-FDG PET imaging in the follow up of endometrial cancer patients: systematic review and meta-analysis of the literature. Gynecol Oncol. 2012 Oct 26;128(2):397-404. Abstract
105. Amant F, Mirza MR, Koskas M, et al. Cancer of the corpus uteri. Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:37-50.Full text Abstract
106. Creasman WT, DeGeest K, DiSaia PJ, et al. Significance of true surgical pathologic staging: a Gynecologic Oncology Group Study. Am J Obstet Gynecol. 1999 Jul;181(1):31-4. Abstract
107. McMeekin DS, Filiaci VL, Thigpen JT, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 Jul;106(1):16-22. Abstract
108. Cho KR, Cooper K, Croce S, et al. International Society of Gynecological Pathologists (ISGyP) endometrial cancer project: guidelines from the Special Techniques and Ancillary Studies Group. Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S114-22.Full text Abstract
109. Abu-Zaid A, Alomar O, Abuzaid M, et al. Preoperative anemia predicts poor prognosis in patients with endometrial cancer: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2021 Mar;258:382-90. Abstract
110. Abu-Zaid A, Alomar O, Baradwan S, et al. Preoperative leukocytosis correlates with unfavorable pathological and survival outcomes in endometrial carcinoma: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2021 Sep;264:88-96. Abstract
111. Dinkel E, Mundinger A, Schopp D, et al. Diagnostic imaging in metastatic lung disease. Lung. 1990;168 Suppl:1129-36. Abstract
112. Davis SD. CT evaluation for pulmonary metastases in patients with extrathoracic malignancy. Radiology. 1991 Jul;180(1):1-12. Abstract
113. Clark TJ, Barton PM, Coomarasamy A, et al. Investigating postmenopausal bleeding for endometrial cancer: cost-effectiveness of initial diagnostic strategies. BJOG. 2006 May;113(5):502-10. Abstract
114. Smith-Bindman R, Kerlikowske K, Feldstein VA, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA. 1998 Nov 4;280(17):1510-7. Abstract
115. Gupta JK, Chien PF, Voit D, et al. Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis. Acta Obstet Gynecol Scand. 2002 Sep;81(9):799-816.Full text Abstract
116. Kinkel K, Kaji Y, Yu KK, et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology. 1999 Sep;212(3):711-8. Abstract
117. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005 Aug 6-12;366(9484):491-505. Abstract
118. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Mar;92(3):744-51. Abstract
119. Creutzberg CL, van Putten WL, Koper PC, et al; PORTEC Study Group. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000 Apr 22;355(9213):1404-11. Abstract
120. Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2015 Dec 2;27(1):16-41.Full text Abstract
121. Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021 Jan;31(1):12-39.Full text Abstract
122. Lancaster JM, Powell CB, Chen LM, et al; SGO Clinical Practice Committee. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2014 Sep 17;136(1):3-7. [Erratum in: Gynecol Oncol. 2015 Sep;138(3):765.] Abstract
123. Auranen A, Joutsiniemi T. A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta Obstet Gynecol Scand. 2011 May;90(5):437-44. Abstract
124. American College of Obstetricians and Gynecologists, Society of Gynecologic Oncology. ACOG practice bulletin no. 147: Lynch syndrome. Obstet Gynecol. 2014 Nov;124(5):1042-54.Full text Abstract
125. American College of Obstetricians and Gynecologists. ACOG committee opinion no. 727: cascade testing: testing women for known hereditary genetic mutations associated with cancer. Obstet Gynecol. 2018 Jan;131(1):e31-4.Full text Abstract
126. National Institute for Health and Care Excellence. Testing strategies for Lynch syndrome in people with endometrial cancer. Oct 2020 [internet publication].Full text
127. Fung MF, Reid A, Faught W, et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol. 2003 Oct;91(1):154-9. Abstract
128. Love CD, Muir BB, Scrimgeour JB, et al. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol. 1999 Jul;17(7):2050-4. Abstract
129. Demirkiran F, Arvas M, Erkun E, et al. The prognostic significance of cervico-vaginal cytology in endometrial cancer. Eur J Gynaecol Oncol. 1995;16(5):403-9. Abstract
130. Bristow RE, Purinton SC, Santillan A, et al. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. Gynecol Oncol. 2006 Nov;103(2):709-13. Abstract
131. Fiorelli JL, Herzog TJ, Wright JD. Current treatment strategies for endometrial cancer. Expert Rev Anticancer Ther. 2008 Jul;8(7):1149-57. Abstract
132. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: uterine neoplasms [internet publication].Full text
133. Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study. Cancer. 1987 Oct 15;60(8 Suppl):2035-41. Abstract
134. Marchocki Z, Cusimano MC, Clarfield L, et al. Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics. Am J Obstet Gynecol. 2021 Oct;225(4):367.e1-39. Abstract
135. Nagar H, Wietek N, Goodall RJ, et al. Sentinel node biopsy for diagnosis of lymph node involvement in endometrial cancer. Cochrane Database Syst Rev. 2021 Jun 9;6(6):CD013021.Full text Abstract
136. Bodurtha Smith AJ, Fader AN, Tanner EJ. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol. 2016 Nov 18;216(5):459-76.e10.Full text Abstract
137. Soliman PT, Westin SN, Dioun S, et al. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol. 2017 May 18;146(2):234-9.Full text Abstract
138. Rossi EC, Kowalski LD, Scalici J, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol. 2017 Feb 1;18(3):384-92. Abstract
139. Holloway RW, Abu-Rustum NR, Backes FJ, et al. Sentinel lymph node mapping and staging in endometrial cancer: a Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol. 2017 May 28;146(2):405-15.Full text Abstract
140. Bogani G, Murgia F, Ditto A, et al. Sentinel node mapping vs. lymphadenectomy in endometrial cancer: a systematic review and meta-analysis. Gynecol Oncol. 2019 Jun;153(3):676-83. Abstract
141. How JA, O'Farrell P, Amajoud Z, et al. Sentinel lymph node mapping in endometrial cancer: a systematic review and meta-analysis. Minerva Ginecol. 2018 Apr;70(2):194-214. Abstract
142. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991 Jan;40(1):55-65. Abstract
143. Badger C, Preston N, Seers K, et al. Physical therapies for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003141.Full text Abstract
144. Galaal K, Donkers H, Bryant A, et al. Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev. 2018 Oct 31;(10):CD006655.Full text Abstract
145. Zhang H, Cui J, Jia L, et al. Comparison of laparoscopy and laparotomy for endometrial cancer. Int J Gynaecol Obstet. 2012 Mar;116(3):185-91. Abstract
146. Obermair A, Janda M, Baker J, et al. Improved surgical safety after laparoscopic compared to open surgery for apparent early stage endometrial cancer: results from a randomised controlled trial. Eur J Cancer.2012 May;48(8):1147-53.Full text Abstract
147. Lin F, Zhang QJ, Zheng FY, et al. Laparoscopically assisted versus open surgery for endometrial cancer - a meta-analysis of randomized controlled trials. Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1315-25. Abstract
148. de la Orden SG, Reza MM, Blasco JA, et al. Laparoscopic hysterectomy in the treatment of endometrial cancer: a systematic review. J Minim Invasive Gynecol. 2008 Jul-Aug;15(4):395-401. Abstract
149. Ju W, Myung SK, Kim Y, et al; Korean Meta-Analysis Study Group. Comparison of laparoscopy and laparotomy for management of endometrial carcinoma: a meta-analysis. Int J Gynecol Cancer. 2009 Apr;19(3):400-6. Abstract
150. Jørgensen SL, Mogensen O, Wu C, et al. Nationwide introduction of minimally invasive robotic surgery for early-stage endometrial cancer and its association with severe complications. JAMA Surg. 2019 Jun 1;154(6):530-8.Full text Abstract
151. Walker JL, Piedmonte MR, Spirtos NM, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol. 2012 Mar 1;30(7):695-700.Full text Abstract
152. Ind T, Laios A, Hacking M, et al. A comparison of operative outcomes between standard and robotic laparoscopic surgery for endometrial cancer: a systematic review and meta-analysis. Int J Med Robot. 2017 Dec;13(4):e1851.Full text Abstract
153. Gaia G, Holloway RW, Santoro L, et al. Robotic-assisted hysterectomy for endometrial cancer compared with traditional laparoscopic and laparotomy approaches: a systematic review. Obstet Gynecol. 2010 Dec;116(6):1422-31. Abstract
154. Orton J, Blake P. Adjuvant external beam radiotherapy (EBRT) in the treatment of endometrial cancer: results of the randomised MRC ASTEC and NCIC CTG EN.5 trial. Paper presented at: 2007 meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. Jun 1-5 2007. J Clin Oncol. 2007 Jun 20;25(18_Suppl):5504.Full text
155. Mariani A, Dowdy SC, Cliby WA, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol. 2008 Apr;109(1):11-8. Abstract
156. Khoury-Collado F, Abu-Rustum NR. Lymphatic mapping in endometrial cancer: a literature review of current techniques and results. Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1163-8. Abstract
157. Frost JA, Webster KE, Bryant A, et al. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 2017 Oct 2;(10):CD007585.Full text Abstract
158. Kitchener H, Swart AM, Qian Q, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009 Jan 10;373(9658):125-36.Full text Abstract
159. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008 Dec 3;100(23):1707-16. Abstract
160. Bristow RE, Zahurak ML, Alexander CJ, et al. FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival. Int J Gynecol Cancer. 2003 Sep-Oct;13(5):664-72. Abstract
161. Chi DS, Welshinger M, Venkatraman ES, et al. The role of surgical cytoreduction in stage IV endometrial carcinoma. Gynecol Oncol. 1997 Oct;67(1):56-60. Abstract
162. Bristow RE, Zerbe MJ, Rosenshein NB, et al. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol. 2000 Aug;78(2):85-91. Abstract
163. Wortman BG, Creutzberg CL, Putter H, et al; PORTEC Study Group. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer. 2018 Oct 25;119(9):1067-74.Full text Abstract
164. Kong A, Johnson N, Kitchener HC, et al. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst. 2012 Nov 7;104(21):1625-34.Full text Abstract
165. van den Heerik ASVM, Horeweg N, de Boer SM, et al. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. Int J Gynecol Cancer. 2021 Apr;31(4):594-604.Full text Abstract
166. Lawrie TA, Green JT, Beresford M, et al. Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers. Cochrane Database Syst Rev. 2018 Jan 23;(1):CD012529.Full text Abstract
167. Nout RA, Putter H, Jürgenliemk-Schulz IM, et al. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer. 2012 Jul;48(11):1638-48.Full text Abstract
168. Creutzberg CL, Nout RA, Lybeert ML, et al; PORTEC Study Group. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e631-8.Full text Abstract
169. Nout RA, van de Poll-Franse LV, Lybeert ML, et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol. 2011 May 1;29(13):1692-700.Full text Abstract
170. Onsrud M, Cvancarova M, Hellebust TP, et al. Long-term outcomes after pelvic radiation for early-stage endometrial cancer. J Clin Oncol. 2013 Nov 1;31(31):3951-6.Full text Abstract
171. Kwak YK, Lee SW, Kay CS, et al. Intensity-modulated radiotherapy reduces gastrointestinal toxicity in pelvic radiation therapy with moderate dose. PLoS One. 2017 Aug 28;12(8):e0183339.Full text Abstract
172. Klopp AH, Yeung AR, Deshmukh S, et al. Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology-RTOG 1203. J Clin Oncol. 2018 Jul 10;36(24):2538-44.Full text Abstract
173. Mundt AJ, Murphy KT, Rotmensch J, et al. Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1154-60. Abstract
174. Einhorn N, Trope C, Ridderheim M, et al. A systematic overview of radiation therapy effects in uterine cancer (corpus uteri). Acta Oncol. 2003;42(5-6):557-61. Abstract
175. Vargo JA, Boisen MM, Comerci JT, et al. Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria. Gynecol Oncol. 2014 Nov;135(2):190-5. Abstract
176. Lanciano RM, Curran WJ, Jr., Greven KM, et al. Influence of grade, histologic subtype, and timing of radiotherapy on outcome among patients with stage II carcinoma of the endometrium. Gynecol Oncol. 1990 Dec;39(3):368-73. Abstract
177. de Boer SM, Powell ME, Mileshkin L, et al; PORTEC Study Group. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019 Sep;20(9):1273-85.Full text Abstract
178. Yi L, Zhang H, Zou J, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in high-risk endometrial cancer: a systematic review and meta-analysis. Gynecol Oncol. 2018 Jun;149(3):612-9. Abstract
179. de Boer SM, Powell ME, Mileshkin L, et al; PORTEC Study Group. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Feb 12;19(3):295-309.Full text Abstract
180. Randall ME, Filiaci V, McMeekin DS, et al. Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early stage endometrial cancer. J Clin Oncol. 2019 Jul 20;37(21):1810-8.Full text Abstract
181. Thigpen T, Brady MF, Homesley HD, et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2001 Jan 15;19(2):364-7. Abstract
182. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999 Jun;17(6):1736-44. Abstract
183. Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Jan;92(1):10-4. Abstract
184. Skeel RT, Khleif S (eds). Handbook of cancer chemotherapy. Philadelphia, PA: Lippincott Williams & Wilkins; 2011.
185. Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer. 2007 Sep-Oct;17(5):964-78. Abstract
186. Polyzos NP, Pavlidis N, Paraskevaidis E, et al. Randomized evidence on chemotherapy and hormonal therapy regimens for advanced endometrial cancer: an overview of survival data. Eur J Cancer. 2006 Feb;42(3):319-26. Abstract
187. Slomovitz BM, Filiaci VL, Walker JL, et al. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: a GOG Foundation study. Gynecol Oncol. 2022 Mar;164(3):481-91. Abstract
188. Lentz SS. Endocrine therapy of endometrial cancer. Cancer Treat Res. 1998;94:89-106. Abstract
189. Martin-Hirsch PP, Bryant A, Keep SL, et al. Adjuvant progestagens for endometrial cancer. Cochrane Database Syst Rev. 2011 Jun 15;(6):CD001040.Full text Abstract
190. Sorbe B, Nordström B, Mäenpää J, et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer. 2009 Jul;19(5):873-8. Abstract
191. Klopp A, Smith BD, Alektiar K, et al. The role of postoperative radiation therapy for endometrial cancer: executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2014 May-Jun;4(3):137-44.Full text Abstract
192. Jones E, Beriwal S, Beyer D, et al. An analysis of appropriate delivery of postoperative radiation therapy for endometrial cancer using the RAND/UCLA Appropriateness Method: executive summary. Adv Radiat Oncol. 2015 Dec 17;1(1):26-34.Full text Abstract
193. Gunderson CC, Fader AN, Carson KA, et al. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012 May;125(2):477-82. Abstract
194. Baker JO. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol. 2012 Apr;125(1):263-70. Abstract
195. Nout RA, Smit VT, Putter H, et al; PORTEC Study Group. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010 Mar 6;375(9717):816-23. Abstract
196. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004 Jun 1;22(11):2159-66.Full text Abstract
197. Miller D, Filiaci V, Gelming G, et al. Late-breaking abstract 1: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Paper presented at: Society of Gynecologic Oncology 2012 Annual Meeting on Women's Cancer. Austin, TX. Mar 24-27 2012. Gynecol Oncol. 2012 Jun;125(3):771-3.Full text
198. Nomura H, Aoki D, Michimae H, et al. Effect of taxane plus platinum regimens vs doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at a high risk of progression: a randomized clinical trial. JAMA Oncol. 2019 Jun 1;5(6):833-40.Full text Abstract
199. Kong A, Johnson N, Kitchener HC, et al. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev. 2012 Apr 18;(4):CD003916.Full text Abstract
200. Geller MA, Ivy JJ, Ghebre R, et al. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol. 2011 Apr;121(1):112-7.Full text Abstract
201. Lu SM, Chang-Halpenny C, Hwang-Graziano J. Sequential versus "sandwich" sequencing of adjuvant chemoradiation for the treatment of stage III uterine endometroid adenocarcinoma. Gynecol Oncol. 2015 Apr;137(1):28-33. Abstract
202. Matei D, Filiaci V, Randall ME, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med. 2019 Jun 13;380(24):2317-26.Full text Abstract
203. Lu KH, Broaddus RR. Endometrial cancer. Reply. N Engl J Med. 2021 Feb 11;384(6):586. Abstract
204. Penson RT, Wenzel LB, Vergote I, et al. Quality of life considerations in gynecologic cancer. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S247-57. Abstract
205. Creutzberg CL, van Putten WL, Koper PC, et al; PORTEC Study Group. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol. 2003 May;89(2):201-9. Abstract
206. Jhingran A, Burke TW, Eifel PJ. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1366-72. Abstract
207. Ho JC, Allen PK, Jhingran A, et al. Management of nodal recurrences of endometrial cancer with IMRT. Gynecol Oncol. 2015 Oct;139(1):40-6.Full text Abstract
208. Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Jan;92(1):4-9. Abstract
209. Sjoquist KM, Martyn J, Edmondson RJ, et al. The role of hormonal therapy in gynecological cancers - current status and future directions. Int J Gynecol Cancer. 2011 Oct;21(7):1328-33. Abstract
210. Ott PA, Bang YJ, Berton-Rigaud D, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 Study J Clin Oncol. 2017 May 10;35(22):2535-41.Full text Abstract
211. O'Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 Study. J Clin Oncol. 2022 Mar 1;40(7):752-61.Full text Abstract
212. O'Malley DM, Bariani GM, Cassier PA, et al. Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study. Gynecol Oncol. 2022 Aug;166(2):245-53.Full text Abstract
213. Makker V, Colombo N, Casado Herráez A, et al; Study 309–KEYNOTE-775 Investigators. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022 Feb 3;386(5):437-48.Full text Abstract
214. Duska LR, Berkowitz R, Matulonis U, et al. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer. Gynecol Oncol. 2005 Jan;96(1):198-203. Abstract
215. US Food and Drug Administration. FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer. Apr 2021 [internet publication].Full text
216. European Medicines Agency. Jemperli (dostarlimab). Oct 2022 [internet publication].Full text
217. ClinicalTrials.gov. Study of TSR-042, an anti-programmed cell death-1 receptor (PD-1) monoclonal antibody, in participants With advanced solid tumors (GARNET). NCT02715284. Nov 2022 [internet publication].Full text
218. Kalinsky K, Hong F, McCourt CK, et al. Effect of capivasertib in patients with an AKT1 E17K-mutated tumor: NCI-MATCH subprotocol EAY131-Y nonrandomized trial. JAMA Oncol. 2021 Feb 1;7(2):271-8.Full text Abstract
219. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006 Jan 1;24(1):36-44.Full text Abstract
220. Edey KA, Rundle S, Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst Rev. 2018 May 15;(5):CD008830.Full text Abstract
221. Rees M, Angioli R, Coleman RL, et al. European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Maturitas. 2020 Apr;134:56-61.Full text Abstract
222. Cella D, Huang H, Homesley HD, et al. Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: results from GOG 184. Gynecol Oncol. 2010 Dec;119(3):538-42. Abstract
223. Zhou X, Yao Z, Bai H, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021 Sep;22(9):1265-74. Abstract
224. Naqash AR, Moey MYY, Cherie Tan XW, et al. Major adverse cardiac events with immune checkpoint inhibitors: a pooled analysis of trials sponsored by the National Cancer Institute - Cancer Therapy Evaluation Program. J Clin Oncol. 2022 Oct 10;40(29):3439-52.Full text Abstract
225. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: management of immunotherapy-related toxicities [internet publication].Full text
226. Cancer Care Ontario Program in Evidence-based Care Gynecology Cancer Disease Site Group. Follow-up after primary therapy for endometrial cancer: a systematic review. Jan 2006 (endorsed Jun 2017) [internet publication].Full text
227. Vergote I, Kjorstad K, Abeler V, et al. A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer. 1989 Sep 1;64(5):1011-6. Abstract
Use of this content is subject to our disclaimer